Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.39 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.39 |
| ▸ | GUSB | P08236 | 4/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8927457 | 0.88 | MAOB (0.42) | MAOBMAOALTB4RLTB4R2GUSB | |
| SCHEMBL8927777 | 0.88 | MAOB (0.42) | MAOBMAOALTB4RLTB4R2GUSB | |
| SCHEMBL11403457 | 0.84 | MAOB (0.39) | MAOBMAOALTB4RLTB4R2GUSB | |
| SCHEMBL28302100 | 0.78 | MAOA (0.45) | MAOBMAOALTB4RLTB4R2GUSB | |
| SCHEMBL27833117 | 0.77 | MAOA (0.48) | MAOBMAOALTB4RLTB4R2GUSB | |
| SCHEMBL171162 | 0.77 | ABCB1 (0.46) | MAOBMAOAGUSBABCB1POLB | |
| SCHEMBL13535591 | 0.76 | MAOB (0.39) | MAOBMAOAGUSBABCB1POLB | |
| SCHEMBL13287870 | 0.75 | MAOB (0.38) | MAOBMAOALTB4RLTB4R2GUSB | |
| SCHEMBL28241766 | 0.74 | ABCB1 (0.37) | MAOBMAOAGUSBABCB1POLB | |
| SCHEMBL7557450 | 0.74 | MAOA (0.45) | MAOBMAOALTB4RLTB4R2GUSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105026392-B | 4,5-dihydro-pyrazolo [3, 4-c] pyrid-2-ones, preparation method and application thereof | 四川海思科制药有限公司 | 2017-05-10 | — | — | CN | disclosed |
| CN-105026392-A | 4,5-dihydro-pyrazolo [3, 4-c] pyrid-2-ones, preparation method and application thereof | SICHUAN HAISCO PHARMACEUTICAL CO LTD | 2015-11-04 | — | — | CN | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | MAOB 2140/4885MAOA 2885/4885LTB4R 1850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.